Abstracts tagged "Pediatric rheumatology"

Abstract Number: 2043 • ACR Convergence 2024
Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study
Fatma Zehra Avci¹, Feyza Nur Azman², Elif Sila Unsal³ and Serdal Ugurlu⁴, ¹Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, ⁴Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) typically begins in childhood. It has been demonstrated that colchicine can reduce FMF attacks, prevent the development of amyloidosis, and…
Abstract Number: 2193 • ACR Convergence 2024
Prospective Evaluation of Reactogenicity and Safety Following COVID-19 Vaccination in Children with a History of MIS-C
Mariana Sanchez Villa¹, Jessica Nguyen², Danielle Guffey³, Leila Sahni⁴, Miriah Gillispie-Taylor⁵, Marietta De Guzman², S. Kristen Sexson Tejtel², Sridevi Devaraj⁴, Flor Munoz⁴ and Tiphanie Vogel², ¹Baylor college of Medicine, Huffman, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Houston, ⁴Baylor COM, Houston, TX, ⁵Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: A rare subset of children who contract SARS-CoV-2 later develop the hyperinflammatory condition known as multisystem inflammatory syndrome in children (MIS-C). There has been…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
James Bistolarides¹, Vidya Sivaraman², Else Bosman³, Linda Wagner-Weiner⁴, Kimberly Morishita⁵, James Nocton¹, Melodee Liegl¹, Amy Pan¹ and David Cabral⁶, and PedVas Investigators Network, ¹Medical College of Wisconsin, Milwaukee, WI, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³UBC, Vancouver, BC, Canada, ⁴University of Chicago, Chicago, IL, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Elena Zholobova³, Elizaveta Krekhova⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sofia Kuzkina⁶, Mikhail Samsonov⁶, Irina Nikishina⁷ and Mikhail Kostik⁵, ¹National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²National Medical Research Center of Children's Health, Moscow, Russia, ³Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁴National Medical Research Centre for Children's Health, Moscow, Russia, ⁵Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁶R-Pharm, Moscow, Russia, ⁷V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
Abstract Number: 1058 • ACR Convergence 2024
Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
Adrienne Ramirez¹, Lisa Walker-Vischer² and Tzielan Lee³, ¹Stanford Medicine - Children's Health, Palo Alto, CA, ²San Jose State University, Campbell, CA, ³Stanford University School of Medicine, Palo Alto, CA

Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…
Abstract Number: 1270 • ACR Convergence 2024
Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Marshall Brown³, Gabrielle Alonzi⁴, Mersine Bryan⁵, Cordelia Burn⁶, Joyce Chang⁴, Jonathan Cogen⁷, Nidhi Naik⁸, Kareena Patel⁹, Emily Zhang⁴, Mary Beth Son¹⁰ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children's Research Institute, Seattle, WA, ⁴Boston Children's Hospital, Boston, MA, ⁵Division of Hospital Medicine, Seattle Children's Hospital, Seattle, WA, ⁶Seattle Children's Hospital, Boston Children's Hospital, Seattle, ⁷Seattle Children’s Hospital, Seattle, WA, ⁸Seattle children's hospital, Bothell, WA, ⁹Seattle Children's Hospital, Seattle, ¹⁰Boston Children's Hospital, Brookline, MA
Background/Purpose: Youth with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to…
Abstract Number: 1317 • ACR Convergence 2024
Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis
Yasmine LAMROUS, Camille LEGLISE, Audrey VANRENTERGHEM, Taieb CHOUAKI and Djamal-Dine DJEDDI, CHU AMIENS PICARDIE, AMIENS, France
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses the most common chronic rheumatologic manifestations in children. It results from the interplay of genetic, environmental, and infectious factors.…
Abstract Number: 1779 • ACR Convergence 2024
Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers
Jessica Turnier¹, Chioma Madubata², Christine Goudsmit³, Sean Ferris³, Celine Berthier³, Zilan Zheng⁴, Sophia Matossian³, Jeff Dvergsten⁵, Meredyth Wilkinson⁶, Lucy R Wedderburn⁷, Gabrielle Morgan⁸, Lauren Pachman⁹, Claudia Lalancette³, Stephen Parker³, Andrew Heaton¹⁰, J. Michelle Kahlenberg³, Gabriela K Fragiadakis² and Jessica Neely⁴, ¹University of Michigan, Saline, MI, ²University of California, San Francisco, San Francisco, CA, ³University of Michigan, Ann Arbor, MI, ⁴UCSF, San Francisco, CA, ⁵Duke University Hospital, Hillsborough, NC, ⁶Great Ormond Street Institute of Child Health, London, United Kingdom, ⁷UCL GOS Institute of Child Health, London, United Kingdom, ⁸Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁰Cure JM, Leesburg, VA
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary…
Abstract Number: 2161 • ACR Convergence 2024
Parent and Youth Report of Psychosocial Functioning in Chronic Childhood Vasculitis
Camille Wilson¹, Kimberly Morishita², Else Bosman³, Alana Leever⁴, Mahmoud Kallash⁵, Anne Dawson¹, David Cabral⁶ and Vidya Sivaraman⁷, and the PedVas investigator network, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital, Ohio State University, Columbus, OH, ⁵Nationwide Children's Hosptial, Columbus, OH, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Nationwide Children's Hospital/ The Ohio State University, Columbus, OH
Background/Purpose: Collaborative research efforts have allowed great strides to advance treatment and care for pediatric patients living with chronic vasculitis. However, little research has been…
Abstract Number: 2195 • ACR Convergence 2024
Pediatric Rheumatology Graduation: A One-Way Bridge to Adult Care?
Kyla Fergason¹, David McDonald¹, Karissa Chesky², Jimin Kim², Tiphanie Vogel¹ and Miriah Gillispie-Taylor³, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: For many patients with childhood onset disease, the transition from pediatric to adult healthcare is difficult, often resulting in lapses in care and increased…
Abstract Number: 2510 • ACR Convergence 2024
The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Francis Lao¹, Cal Robinson², Dorota Borovski³, KAREN BEATTIE⁴, Joycelyne Ewusie⁵, Rahul Chanchlani³ and Michelle Batthish⁶, ¹The Hospital for Sick Children, Hamilton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³McMaster University, Hamilton, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵McMaster University, Hamilton, ⁶McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
Abstract Number: 2653 • ACR Convergence 2024
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Elaine Yung¹, Xiaoxuan Liu², Bin Huang³, Michael Wagner¹, Minal Aundhia², Chen Chen⁴ and hermine brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cin, OH, ⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life. A common goal of treatment is to…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…

« Previous Page
1
…
4
5
6
7
8
…
52
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.